Bezlotoxumab Versus FMT for Multiple Recurrent CDI

Inclusion Criteria: * 18-90 years old * diarrhea (3 or more unformed stools per 24h for two consecutive days; or \>= 8 unformed stools per 48h) XML File Identifier: KqQEbBLRYEZjGgsIl5GcI+NXCyM= Page 10/22 * positive PCR test for toxin A/B genes and/or positive toxin EIA for current and previous episodes (low PCR cycle threshold value when only PCR performed) * a minimum of two prior CDI episodes * previous episode is maximum of 3 months prior to the current episode * the current episode responds well to Standard of Care treatment (vancomycin or fidaxomicin orally). * Assessment of the severity of the disease will be performed according to the ESCMID recommendations. * Both mild and severe CDI will be included Exclusion Criteria: * Severe complicated CDI, i.e presence of: hypotension, septic shock, elevated serum lactate, ileus, toxic megacolon, bowel perforation, or any fulminant course of disease. * ICU admission for underlying disease * pregnancy or current desire for pregnancy * breastfeeding * (prolonged) use of antibiotics (other than for treatment of CDI) during the study period or directly after the intervention * previous use of bezlotoxumab or fecal microbiota transplantation * a history of underlying congestive heart failure (potential safety signal phase-III trail bezlotoxumab). * Diagnosis of inflammatory bowel disease in medical history.